These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35118420)

  • 21. CpG-Conjugated Silver Nanoparticles as a Multifunctional Nanomedicine to Promote Macrophage Efferocytosis and Repolarization for Atherosclerosis Therapy.
    Tang C; Wang H; Guo L; Zou C; Hu J; Zhang H; Zhou W; Yang G
    ACS Appl Mater Interfaces; 2023 Nov; ():. PubMed ID: 37910772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD47-SIRPα signaling-inspired engineered monocytes for preventing the progression of atherosclerotic plaques.
    Xia Q; Liu F; Zhou Y; Yang G; Li F; Liang T; Liu J; Li W; Huang Y; Zhu C
    Mater Today Bio; 2024 Oct; 28():101178. PubMed ID: 39211288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Evidence Supports a Major Role for Akt1 in VSMCs During Atherogenesis.
    Rotllan N; Wanschel AC; Fernández-Hernando A; Salerno AG; Offermanns S; Sessa WC; Fernández-Hernando C
    Circ Res; 2015 May; 116(11):1744-52. PubMed ID: 25868464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impaired Mechanism and Facilitated Therapies of Efferocytosis in Atherosclerosis.
    Wang Z; Su J; Gong F; Xue L; Su Z
    J Cardiovasc Pharmacol; 2022 Sep; 80(3):407-416. PubMed ID: 35853202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folate-Modified Liposomes Loaded with Telmisartan Enhance Anti-Atherosclerotic Potency for Advanced Atherosclerosis in ApoE
    Fang D; Jin Q; Jin Z; Wang F; Huang L; Yang Y; He Z; Liu Y; Jiang C; Wu J; Song X
    J Biomed Nanotechnol; 2019 Jan; 15(1):42-61. PubMed ID: 30480514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in Anti-metabolic Disease Treatments Targeting CD47.
    Gao L; He Z; Wu Y
    Curr Pharm Des; 2022; 28(46):3720-3728. PubMed ID: 36201266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice.
    Kyaw T; Winship A; Tay C; Kanellakis P; Hosseini H; Cao A; Li P; Tipping P; Bobik A; Toh BH
    Circulation; 2013 Mar; 127(9):1028-39. PubMed ID: 23395974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.
    Evans RJ; Lavin B; Phinikaridou A; Chooi KY; Mohri Z; Wong E; Boyle JJ; Krams R; Botnar R; Long NJ
    Nanotheranostics; 2020; 4(4):184-194. PubMed ID: 32637296
    [No Abstract]   [Full Text] [Related]  

  • 29. Ca
    Tajbakhsh A; Kovanen PT; Rezaee M; Banach M; Sahebkar A
    J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticles functionalised with an anti-platelet human antibody for in vivo detection of atherosclerotic plaque by magnetic resonance imaging.
    Jacobin-Valat MJ; Laroche-Traineau J; Larivière M; Mornet S; Sanchez S; Biran M; Lebaron C; Boudon J; Lacomme S; Cérutti M; Clofent-Sanchez G
    Nanomedicine; 2015 May; 11(4):927-37. PubMed ID: 25684334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasound Microbubble Delivery Targeting Intraplaque Neovascularization Inhibits Atherosclerotic Plaque in an APOE-deficient Mouse Model.
    Yuan H; Hu H; Sun J; Shi M; Yu H; Li C; Sun YU; Yang Z; Hoffman RM
    In Vivo; 2018; 32(5):1025-1032. PubMed ID: 30150423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly Bright AIE Nanoparticles by Regulating the Substituent of Rhodanine for Precise Early Detection of Atherosclerosis and Drug Screening.
    Wang K; Gao H; Zhang Y; Yan H; Si J; Mi X; Xia S; Feng X; Liu D; Kong D; Wang T; Ding D
    Adv Mater; 2022 Mar; 34(9):e2106994. PubMed ID: 34921573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery.
    Yu M; Ortega CA; Si K; Molinaro R; Schoen FJ; Leitao RFC; Xu X; Mahmoudi M; Ahn S; Liu J; Saw PE; Lee IH; Brayner MMB; Lotfi A; Shi J; Libby P; Jon S; Farokhzad OC
    Theranostics; 2018; 8(21):6008-6024. PubMed ID: 30613278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.
    Yurdagul A; Doran AC; Cai B; Fredman G; Tabas IA
    Front Cardiovasc Med; 2017; 4():86. PubMed ID: 29379788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased lymphocyte activation and atherosclerosis in CD47-deficient mice.
    Engelbertsen D; Autio A; Verwilligen RAF; Depuydt MAC; Newton G; Rattik S; Levinsohn E; Saggu G; Jarolim P; Wang H; Velazquez F; Lichtman AH; Luscinskas FW
    Sci Rep; 2019 Jul; 9(1):10608. PubMed ID: 31337788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice.
    Hamzah J; Kotamraju VR; Seo JW; Agemy L; Fogal V; Mahakian LM; Peters D; Roth L; Gagnon MK; Ferrara KW; Ruoslahti E
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7154-9. PubMed ID: 21482787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms and consequences of efferocytosis in advanced atherosclerosis.
    Thorp E; Tabas I
    J Leukoc Biol; 2009 Nov; 86(5):1089-95. PubMed ID: 19414539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dead cell and debris clearance in the atherosclerotic plaque: Mechanisms and therapeutic opportunities to promote inflammation resolution.
    Dhawan UK; Singhal A; Subramanian M
    Pharmacol Res; 2021 Aug; 170():105699. PubMed ID: 34087352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New insights into the etiopathogenesis of atherosclerosis and atherothrombosis].
    Herman AG
    Bull Mem Acad R Med Belg; 2006; 161(3-4):213-25; discussion 226-7. PubMed ID: 17172227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomimetic-Coated Nanoplatform with Lipid-Specific Imaging and ROS Responsiveness for Atherosclerosis-Targeted Theranostics.
    Ma B; Xu H; Wang Y; Yang L; Zhuang W; Li G; Wang Y
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35410-35421. PubMed ID: 34286950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.